Literature DB >> 22472963

Validation of the Cannabis Abuse Screening Test in a sample of cannabis inpatients.

Stéphane Legleye1, Ludwig Kraus, Daniela Piontek, Olivier Phan, Céline Jouanne.   

Abstract

The present study aims at validating the Cannabis Abuse Screening Test (CAST) in a clinical sample of adolescent and young adult cannabis users seeking treatment. Applying a classical test theory approach using DSM-IV diagnoses as gold standard, two versions of the CAST questionnaire are compared. The sample consisted of 140 subjects aged 15-26 years (mean 18.9) recruited from two cannabis treatment centers. Gold standard diagnoses were assessed using the Adolescent Diagnostic Interview-Light. Internal structure and consistency of the CAST were assessed by principal component analysis and Cronbach's α. Optimal thresholds were defined using receiver operating characteristic analysis. Both the binary and the full test version revealed unidimensional structures with moderate to satisfactory internal consistency (α = 0.66 and 0.73). Screening properties were unsatisfactory when the CAST was compared against cannabis dependence. With regard to cannabis use disorders, both test versions yielded comparable and good sensitivity and specificity at cut-off 3 (binary: 92.2%, 66.7%) and 6 (full: 93.0%, 66.7%). Overall, the full CAST may be used for screening cannabis use disorders in clinical settings. Further research may use validation methods that do without gold standard.
Copyright © 2012 S. Karger AG, Basel.

Mesh:

Year:  2012        PMID: 22472963     DOI: 10.1159/000336553

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  7 in total

1.  The Cannabis Abuse Screening Test (CAST) revisited: examining measurement invariance by age.

Authors:  Sharon R Sznitman
Journal:  Int J Methods Psychiatr Res       Date:  2016-10-10       Impact factor: 4.035

2.  Baclofen in the management of cannabis dependence syndrome.

Authors:  Bruce Imbert; Nathalie Labrune; Christophe Lancon; Nicolas Simon
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

3.  The association of type of cannabis product used and frequency of use with problematic cannabis use in a sample of young adult cannabis users.

Authors:  Kelsey A Simpson; Junhan Cho; Jessica L Barrington-Trimis
Journal:  Drug Alcohol Depend       Date:  2021-06-24       Impact factor: 4.852

4.  Internal consistency and measurement equivalence of the cannabis screening questions on the paper-and-pencil face-to-face ASSIST versus the online instrument.

Authors:  Yasser Khazaal; Anne Chatton; Grégoire Monney; Audrey Nallet; Riaz Khan; Daniele Zullino; Jean-François Etter
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-03-08

5.  Ecological Momentary Assessment and Smartphone Application Intervention in Adolescents with Substance Use and Comorbid Severe Psychiatric Disorders: Study Protocol.

Authors:  Xavier Benarous; Yves Edel; Angèle Consoli; Julie Brunelle; Jean-François Etter; David Cohen; Yasser Khazaal
Journal:  Front Psychiatry       Date:  2016-09-20       Impact factor: 4.157

6.  Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and addictive phenotypes.

Authors:  Tom G Richardson; Camelia Minica; Jon Heron; Jeremy Tavare; Alasdair MacKenzie; Ian Day; Glyn Lewis; Matthew Hickman; Jacqueline M Vink; Joel Gelernter; Henry R Kranzler; Lindsay A Farrer; Marcus Munafò; David Wynick
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2014-09-16       Impact factor: 3.568

7.  Factors and motivations associated with use of e-cigarette among primary care patients in a prospective cohort study: e-TAC study protocol.

Authors:  Shérazade Kinouani; Philippe Castéra; Catherine Laporte; François Pétrègne; Bernard Gay
Journal:  BMJ Open       Date:  2016-06-15       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.